Tiprelestat: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 17 patientsc19early.org

Tiprelestat for COVID-19

Serious outcome risk
Tiprelestat
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−189%
Mortality (1)−189%
ICU admission (1)22%
RCTs (1)−189%
Late (1)−189%
00.511.5+
← Tiprelestat
reduces riskIncreased
risk →
c19early.org
October 2026

Tiprelestat COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.32death1/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.321/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bergs (DB RCT)22%0.78 · 0.07–8.659 (n)8 (n)
Late treatment22%0.78 · 0.07–8.659 (n)8 (n)22% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies22%0.78 · 0.07–8.659 (n)8 (n)22% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.32death1/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.32death1/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.321/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →
c19early.org
October 2026

Tiprelestat COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bergs (DB RCT)−189%2.89 · 0.13–62.32death1/90/8
Late treatment−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.51
All studies−189%2.89 · 0.13–62.321/90/8189% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+
Rotate screen for more detailsIncrease width for more details
← Tiprelestat
reduces riskTiprelestat
increases risk →